Key Studies We've Supported
The following table showcases example clinical studies and registries that have successfully utilized the Studymaker platform for high-integrity data collection.
PERC Rule
Pulmonary Embolism
Screened over 8,000 emergency patients. Found that low-risk individuals meeting Pulmonary Embolism Rule-out Criteria(PERC) could safely avoid pulmonary embolism testing, with only a ~1% missed event rate.
EM Hypotension
Hypotension
Cohort study of nearly 4,800 emergency patients found that low blood pressure in the ED more than doubled the risk of in-hospital death and significantly increased sudden unexpected mortality.
Lactates
A randomized multicenter trial of 300 sepsis patients found that guiding early treatment using lactate clearance was as effective as central venous oxygen monitoring, supporting a simpler, less invasive approach to care.
Sepsis
EMPEROR registry
Pulmonary embolism
A multicenter registry of 1,800+ patients across 22 U.S. emergency departments found that pulmonary embolism outcomes are generally favorable, but early treatment practices remain inconsistent, highlighting the need for more standardized care.
Multicenter Procalcitonin Monitoring Sepsis(MOSES)
Sepsis
A large U.S. multicenter study of 858 severe sepsis patients found that those whose procalcitonin levels did not drop by at least 80% within four days had nearly double the risk of death within 28 days.
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction(UPSTREAM) registry
Myocardial infarction
A multicenter U.S. registry studying how heart attack patients (NSTEMI) are treated before cardiac catheterization, focusing on early use of oral antiplatelet medications like ticagrelor.
The study tracks treatment decisions, risk assessment, and outcomes from emergency department arrival through hospitalization—and follows some patients for 30 days after discharge.
Takeaway: Early (“upstream”) antiplatelet treatment plays a critical role in patient outcomes, resource use, and continuity of care, helping inform best practices for managing NSTEMI before definitive diagnosis.
A large multicenter U.S. study of over 3,300 heart attack patients (NSTEMI) examined outcomes when oral antiplatelet therapy was given early—at least four hours before angiography.
The study found very low rates of complications, including minimal bleeding and low in-hospital mortality, along with short hospital stays, regardless of the specific medication used.
Takeaway: Administering antiplatelet therapy early in the treatment process appears to be safe and effective, supporting its use before definitive cardiac diagnosis in NSTEMI patients.
SOAR Registry (Anticoagulants & Emergency Care)
Anticoagulants
A national, multicenter study of over 1,500 patients examined how emergency departments manage bleeding and bleeding risks in patients taking oral anticoagulants.
The study found that care approaches varied widely, with differences in testing, treatment, and use of reversal therapies—highlighting inconsistency in managing these high-risk patients.
Takeaway: As anticoagulant use rises, there is a growing need for more standardized, evidence-based protocols to improve safety and outcomes in emergency care
AMPED Study (Pain Severity & Return to Work)
Pain management
A study of over 600 emergency department patients found that those experiencing higher pain levels after discharge were less likely to return to work in the following days.
Even small increases in daily pain were linked to delays in returning to normal activity, with most patients taking a few days to resume work.
Takeaway: Effective pain management after emergency visits is critical—not just for comfort, but for helping patients recover function and return to daily life sooner.
FebriDx Study (Rapid Testing for Respiratory Infections)
Respiratory infections
A multicenter U.S. clinical trial evaluated the accuracy of a rapid, point-of-care test (FebriDx) for diagnosing acute upper respiratory infections, including in patients with and without fever.
The study assessed how well the test could distinguish between different types of infections at the point of care, supporting faster clinical decision-making.
Takeaway: Rapid diagnostic tools like FebriDx can help clinicians quickly and accurately assess infections, improving treatment decisions and reducing unnecessary antibiotic use.
01
FDA COMPLIANCE
Comprehensive mastery of CDRZ and FDA 21 CFR Part 11 requirements, ensuring all clinical data maintains strict integrity and regulatory readiness for submission.
02
HIPAA SECURITY
Engineered with HIPAA-compliant encryption standards and robust access controls, providing secure hosting for sensitive patient health information and trial outcomes.
03
EDC SYSTEMS
Expert implementation of Electronic Data Capture systems specialized for multi-center clinical trials, streamlining the transition from paper to digital capture files.
04
eCOA EXPERTISE
Deep technical knowledge in Electronic Clinical Outcome Assessment, leveraging mobile-first technology to capture real-time patient data with maximum precision.